and binding to Cdk2. CyclinE:Cdk2 plays an additional important phosphorylation role in the G1-to-S transition. Particularly, CyclinE:Cdk2 promotes a positive...
34 KB (4,581 words) - 11:50, 4 April 2024
complementarity. S2 cells were then transfected with Drosophila cyclin E dsRNA. Cycline E is an essential gene for cell cycle progression into the S phase. Cyclin...
36 KB (3,836 words) - 14:30, 19 April 2024
S phase by releasing the E2F family of transcription factors (inducing CyclinE expression). Additionally, Cyclin E1 is more easily replicated in BLBC...
15 KB (1,741 words) - 11:28, 4 January 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
105 KB (12,670 words) - 08:02, 23 August 2024
Ian". Australian Bureau of Meteorology. Retrieved 14 August 2012. Massive Cycline Threatens Northwest Australia (Report). GREENPEACE Climate Impacts Database...
32 KB (2,817 words) - 03:19, 9 August 2024
p27 is phosphorylated by Src at tyrosine 74 or 88 it ceases to inhibit cyclinE-cdk2. Src was also shown to reduce the half life of p27 meaning it is degraded...
41 KB (5,152 words) - 16:17, 13 October 2024
possible tumor suppression Serine/threonine kinase 11 Regulates cell polarity Cycline-dependent kinase inhibitor 2A Stabilizes p53 Folliculin Unknown, possible...
20 KB (1,228 words) - 09:44, 11 August 2024
J., Paterlini, P., Wang, J., Chenivesse, X., Henglein B., Bréchot, C. Cycline A et cancer. In Médecine et Science, 9: 676–683, 1993. Buendia, M.A., Paterlini...
25 KB (3,626 words) - 13:34, 24 June 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
20 KB (2,490 words) - 08:20, 11 September 2022
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
26 KB (3,229 words) - 22:04, 18 August 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
22 KB (2,797 words) - 11:53, 3 June 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
24 KB (3,047 words) - 04:40, 4 January 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
25 KB (3,214 words) - 11:43, 3 June 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
25 KB (3,183 words) - 04:46, 19 October 2022
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
24 KB (3,031 words) - 08:14, 3 December 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
21 KB (2,590 words) - 21:44, 18 August 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
20 KB (2,420 words) - 03:17, 18 October 2022
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
25 KB (3,040 words) - 03:19, 3 December 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
32 KB (3,957 words) - 10:58, 23 December 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
26 KB (3,208 words) - 11:46, 3 June 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
19 KB (2,284 words) - 17:45, 29 September 2022
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
24 KB (2,990 words) - 01:08, 4 December 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
26 KB (3,063 words) - 10:47, 11 April 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
20 KB (2,357 words) - 18:45, 14 October 2022
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
20 KB (2,486 words) - 00:27, 19 August 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
31 KB (3,859 words) - 11:46, 3 June 2024
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
23 KB (2,861 words) - 14:37, 3 December 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
24 KB (2,972 words) - 09:47, 18 August 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
20 KB (2,468 words) - 09:01, 18 August 2023
as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors. Lastly, autoimmune disease patients...
21 KB (2,664 words) - 23:57, 2 October 2024